

Sandra P D'angelo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4184683/publications.pdf>

Version: 2024-02-01

73
papers

12,787
citations

172207

29
h-index

133063

59
g-index

74
all docs

74
docs citations

74
times ranked

17768
citing authors

#	ARTICLE	IF	CITATIONS
1	Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection. <i>Annals of Surgical Oncology</i> , 2022, 29, 640-648.	0.7	17
2	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	0.8	13
3	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1507-1517.	3.2	3
4	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. , 2022, 10, e003302.		16
5	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
6	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 939-947.	3.2	10
7	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. <i>Nature Communications</i> , 2022, 13, .	5.8	63
8	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	21
9	Immunotherapy in Sarcoma. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 381-397.	0.6	9
10	Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 73.	0.1	0
11	The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 834-844.	2.3	11
12	Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor. <i>Oncologist</i> , 2021, 26, e710-e714.	1.9	3
13	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq1 1 0.784314 rgBT /Ove	1.1	52
14	The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast. <i>Histopathology</i> , 2021, 79, 836-846.	1.6	9
15	Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases. <i>Frontiers in Oncology</i> , 2021, 11, 725484.	1.3	4
16	Efficacy and immune-related adverse event associations in avelumab-treated patients. , 2020, 8, e001427.		16
17	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 5448-5455.	3.2	12
18	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. <i>Future Oncology</i> , 2020, 16, 2089-2099.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. <i>JCO Precision Oncology</i> , 2020, 4, 1350-1360.	1.5	18
20	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. , 2020, 8, e000674.		132
21	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	1.1	11
22	Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. <i>Sarcoma</i> , 2020, 2020, 1-8.	0.7	2
23	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	3.4	125
24	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2019, 37, 282-290.	1.2	32
25	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101
26	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	2.0	21
27	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
28	Immune Checkpoint Inhibitors in Sarcoma. , 2019, , 125-137.		0
29	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology</i> , The, 2018, 19, 416-426.	5.1	517
30	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e180077.	3.4	304
31	Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. <i>Onc Immunology</i> , 2018, 7, e1372081.	2.1	37
32	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1-year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
33	Cytokine release syndrome after radiation therapy: case report and review of the literature. , 2018, 6, 1.		54
34	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	7.7	313
35	18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 192-192.	0.8	11
36	Association between objective responses (OR) and overall survival (OS) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 193-193.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	0.8	458
38	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 319-330.e1.	0.4	96
39	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 2972-2980.	3.2	106
40	Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1837-1845.	0.7	28
41	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11001-11001.	0.8	26
42	A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11007-11007.	0.8	26
43	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11008-11008.	0.8	32
44	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11010-11010.	0.8	3
45	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1^{c259}t in HLA-A2⁺ patients with synovial sarcoma (NCT01343043).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3000-3000.	0.8	20
46	First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9530-9530.	0.8	10
47	A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3097-TPS3097.	0.8	1
48	Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc).. <i>Journal of Clinical Oncology</i> , 2017, 35, e22518-e22518.	0.8	1
49	A phase Ib study of BGI398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11039-11039.	0.8	0
50	Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e558-e564.	1.8	8
51	Reply to A. Indini et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1018-1019.	0.8	0
52	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	1.6	247
53	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With<i>CDK4</i>Inhibitor Palbociclib. <i>JAMA Oncology</i> , 2016, 2, 937.	3.4	241
54	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	5.1	1,034

#	ARTICLE	IF	CITATIONS
55	Current status of engineered T-cell therapy for synovial sarcoma. <i>Immunotherapy</i> , 2016, 8, 1073-1080.	1.0	15
56	Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3166-3174.	0.8	133
57	Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. <i>Oncology</i> , 2015, 89, 205-214.	0.9	38
58	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. <i>Human Pathology</i> , 2015, 46, 357-365.	1.1	252
59	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 375-384.	5.1	2,353
60	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. <i>Oncologist</i> , 2015, 20, 1245-1246.	1.9	25
61	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	0.8	892
62	Abstract 4707: Genetically engineered NY-ESO-1-specific T cells in HLA-A2+ patients with synovial sarcoma. , 2015, , .		2
63	A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10507-10507.	0.8	16
64	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1118-1127.	2.1	131
65	Phase II Study of the G1-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation. <i>Clinical Lung Cancer</i> , 2014, 15, 405-410.	1.1	63
66	Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2024-2028.	0.8	370
67	Ipilimumab for Patients With Advanced Mucosal Melanoma. <i>Oncologist</i> , 2013, 18, 726-732.	1.9	140
68	Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers. <i>Clinical Cancer Research</i> , 2012, 18, 6169-6177.	3.2	503
69	Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1815-1822.	0.5	160
70	Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2011, 6, 569-575.	0.5	124
71	A Case Series of Dose-Limiting Peripheral Edema Observed in Patients Treated with Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2011, 6, 624-626.	0.5	18
72	Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 141, 476-480.	0.4	40

#	ARTICLE	IF	CITATIONS
73	Incidence of <i>EGFR</i> Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2011, 29, 2066-2070.	0.8	247